Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-arterial [90]Y-DOTATOC for Neuroendocrine Tumor Liver Metastases
NCT03724409Phase 1Terminated
- Start
- Oct 2018
- Primary completion
- Mar 2021
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label trial of yttrium-90 edotreotide in Neuroendocrine Neoplasm (NEN) (6 cohorts). Primary endpoints: Change in liver enzymes at 6 weeks, Change in platelet counts at 6 weeks and 1 more. Started Oct 2018; status: terminated.
02
Drugs
yttrium-90 edotreotide
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT03724409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03724409.